Sorafenib in non-small cell lung cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 9, 2012, Pages 1417-1426

  Zhang, Jianjun ^a   Gold, Kathryn A ^a   Kim, Edward ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

NSCLC; Sorafenib; Targeted therapy; TKI

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN; PROTEIN KRAS; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING; BLOOD CLOTTING DISORDER; CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ELECTROLYTE BLOOD LEVEL; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENE TRANSLOCATION; HAND FOOT SKIN REACTION; HUMAN; HYPERTENSION; INFECTION; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RASH; RETINOPATHY; REVIEW; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 84865312708     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.699039     Document Type: Review

References (76)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61(4):212-36
2. Wahbah M, Boroumand N, Castro C, et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4, 439 cases. Ann Diagn Pathol 2007;11(2):89-96 (Pubitemid 46350914)
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8 (Pubitemid 34438899)
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32 (Pubitemid 41058344)
5. Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59(10):828-36 (Pubitemid 39389621)
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50 (Pubitemid 44917502)
7. de Marinis F, Grossi F. Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008;13(Suppl 1):14-20
8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
9. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14(3):253-63
10. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374(9699):1432-40
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91 (Pubitemid 41095154)
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39 (Pubitemid 38637993)
13. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12(24):7232-41 (Pubitemid 46095394)
14. Pirker R, Pereira JR, von Pawel J, et al. Egfr expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 flex study. Lancet Oncol 2012;13(1):33-42
15. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
16. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring alk gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12(11):1004-12
17. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12(2):175-80
18. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: is kras a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol 2010;28(31):4769-77
19. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235(4787):442-7 (Pubitemid 17009577)
20. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267(16):10931-4
21. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999;6(8):R217-24 (Pubitemid 29380763)
22. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
23. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996;32A(14):2451-60
24. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001;28(6):536-42 (Pubitemid 33134412)
25. Shibuya M, Claesson-Welsh L. Signal transduction by vegf receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006;312(5):549-60 (Pubitemid 43290332)
26. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated notch4 in embryonic endothelium. Proc Natl Acad Sci USA 2001;98(10):5643-8 (Pubitemid 32435695)
27. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase iii trial (avail). Ann Oncol 2010;21(9):1804-9
28. Erber R, Thurnher A, Katsen AD, et al. combined inhibition of vegf and pdgf signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40
29. Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13(14):4209-17 (Pubitemid 47105985)
30. Batchelor TT, Sorensen AG, di Tomaso E, et al. Azd2171, a pan-vegf receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11(1):83-95 (Pubitemid 46075199)
31. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of vegf signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309 (Pubitemid 41443415)
32. Wilhelm SM, Carter C, Tang L, et al. Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109 (Pubitemid 39331023)
33. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13(9):1001-11
34. Maurer G, Tarkowski B, Baccarini M. Raf kinases in cancer-roles and therapeutic opportunities. Oncogene 2011;30(32):3477-88
35. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead braf and oncogenic ras cooperate to drive tumor progression through craf. Cell 2010;140(2):209-21
36. Davies H, Bignell GR, Cox C, et al. Mutations of the braf gene in human cancer. Nature 2002;417(6892):949-54 (Pubitemid 34716871)
37. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47 (Pubitemid 41653105)
38. Kemmer K, Corless CL, Fletcher JA, et al. Kit mutations are common in testicular seminomas. Am J Pathol 2004;164(1):305-13 (Pubitemid 38364614)
39. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of kit mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a cancer and leukemia group b study. J Clin Oncol 2006;24(24):3904-11 (Pubitemid 46630738)
40. Kindler T, Lipka DB, Fischer T. Flt3 as a therapeutic target in aml: still challenging after all these years. Blood 2010;116(24):5089-102
41. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the raf/mek/erk pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model plc/prf/5. Cancer Res 2006;66(24):11851-8 (Pubitemid 46094197)
42. Wilhelm S, Chien DS. Bay 43-9006: preclinical data. Curr Pharm Des 2002;8(25):2255-7 (Pubitemid 35189898)
43. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
44. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;56(2):125-34 (Pubitemid 46089673)
45. Dy GK, Hillman SL, Rowland KM Jr, et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north central cancer treatment group study n0326. Cancer 2010;16(24):5686-93
46. Flaherty KT, Schiller J, Schuchter LM, et al. A phase i trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14(15):4836-42
47. Okamoto I, Miyazaki M, Morinaga R, et al. Phase i clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 2010;28(6):844-53
48. Scagliotti G, Novello S, von Pawel J, et al. Phase iii study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42.
49. Gatzemeier U, Eisen T, Santoro A, et al. Sorafenib (s) + gemcitabine/cisplatin (gc) vs gc alone in the first-line treatment of advanced non-small cell lung cancer (nsclc): Phase iii nsclc research experience utilizing sorafenib (nexus) trial. Ann Oncol 2010;21(S 8):LBA16
50. Blumenschein G, Molina J, Lathia C, et al. Phase i dose-escalation study of sorafenib in combination with bevacizumab (b), paclitaxel (p), and carboplatin (c) for the treatment of advanced nonsquamous non-small cell lung cancer (nsclc). ASCO Annu Meeting 2011;2029:7565
51. Molina J, Dy G, Foster N, et al. A randomized phase ii study of pemetrexed (pem) with or without sorafenib (s) as second-line therapy in advanced non-small cell lung cancer (nsclc) of nonsquamous histology: ncctg n0626 study. ASCO Annu Meeting 2011;2029:7513
52. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase ii, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274-80
53. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase i trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13(9):2684-91 (Pubitemid 46788036)
54. Gridelli C, Rossi A, Mongillo F, et al. A randomized phase ii study of sorafenib/gemcitabine or sorafenib/ erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics. Clin Lung Cancer 2007;8(6):396-8 (Pubitemid 46918286)
55. Gutierrez M, Kummar S, Allen D, et al. A phase ii study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer (nsclc). ASCO Annu Meeting 2008;2026:19084
56. Kelly RJ, Rajan A, Force J, et al. Evaluation of kras mutations, angiogenic biomarkers, and dce-mri in patients with advanced non-small-cell lung cancer receiving sorafenib. Clin Cancer Res 2011;17(5):1190-9
57. Schiller J, Lee J, Hanna N, et al. A randomized discontinuation phase ii study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. ASCO Annu Meeting 2008;2026(2020):8014
58. Kim ES, Herbst RS, Wistuba II, et al. The battle trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
59. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (interest): a randomised phase iii trial. Lancet 2008;372(9652):1809-18
60. Spigel DR, Burris HA III, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase ii trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(18):2582-9
61. Lind JS, Dingemans AM, Groen HJ, et al. A multicenter phase ii study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16(11):3078-87
62. Gridelli C, Morgillo F, Favaretto A, et al. Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase ii study. Ann Oncol 2011;22(7):1528-34
63. Cho B, Kim S, Heo D, et al. A multicenter phase ii study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (nsclc). ASCO Annu Meeting 2010;2028(2015S):7547
64. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the vegf pathway. Nat Rev Clin Oncol 2009;6(8):465-77
65. Gridelli C, Maione P, Del Gaizo F, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007;12(2):191-200
66. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80 (Pubitemid 34879334)
67. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7 (Pubitemid 32267972)
68. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med 2011;364(26):2507-16
69. Salgia R. Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer 2011;117(17):3889-99
70. Horn L, Dahlberg SE, Sandler AB, et al. Phase ii study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: eastern cooperative oncology group study e3501. J Clin Oncol 2009;27(35):6006-11
71. Dingemans AM, de Langen AJ, van den Boogaart V, et al. First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase ii study including molecular imaging. Ann Oncol 2011;22(3):559-66
72. Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;83(7391):613-17
73. Zhang W, Lee J, Schiller JH, et al. Use of germline polymorphisms in vegf to predict tumor response and progression-free survival in non-small cell lung cancer (nsclc) patients treated with sorafenib: Subset pharmacogenetic analysis of eastern cooperative oncology group (ecog) trial e2501. ASCO Annu Meeting 2010;2028:2015S-7607S
74. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer biol ther 2012;13(5):247-63
75. Das M, Wakelee H. Targeting vegf in lung cancer. Expert Opin Ther Targets 2012;16(4):395-406
76. Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and nsclc: Clinical update and. future directions. Crit Rev Oncol Hematol Mar 8, 2012